Edition:
India

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

1.73USD
19 Jul 2019
Change (% chg)

$-0.22 (-11.28%)
Prev Close
$1.95
Open
$1.92
Day's High
$1.96
Day's Low
$1.72
Volume
187,795
Avg. Vol
132,865
52-wk High
$12.50
52-wk Low
$1.42

Latest Key Developments (Source: Significant Developments)

Arbutus Announces Preliminary Early-Stage Clinical Trial Results For AB-506
Tuesday, 16 Jul 2019 

July 15 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES PRELIMINARY PHASE 1A/1B CLINICAL TRIAL RESULTS FOR AB-506, AN ORAL CAPSID INHIBITOR IN DEVELOPMENT FOR PEOPLE WITH CHRONIC HEPATITIS B.ARBUTUS BIOPHARMA CORP - PHASE 1A/1B CLINICAL TRIAL TO CONTINUE WITH ENROLLMENT OF FURTHER COHORTS.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS OR CLINICALLY SIGNIFICANT SAFETY FINDINGS WERE OBSERVED IN HEALTHY SUBJECTS FOR AB-506.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN CHRONIC HEPATITIS B SUBJECTS.  Full Article

Arbutus Sells Part Of Its Onpattro Royalty Interest To Omers
Wednesday, 3 Jul 2019 

July 2 (Reuters) - Arbutus Biopharma Corp ::PRESS RELEASE - ARBUTUS SELLS PART OF ITS ONPATTRO™ (PATISIRAN) ROYALTY INTEREST TO OMERS.ARBUTUS BIOPHARMA CORP - ARBUTUS TO RECEIVE $20 MILLION IN GROSS PROCEEDS BEFORE ADVISORY FEES WHILE RETAINING SIGNIFICANT DOWNSTREAM ECONOMICS.ARBUTUS BIOPHARMA CORP - RUNWAY EXTENDED WITH NON-DILUTIVE CAPITAL.ARBUTUS BIOPHARMA CORP - ARBUTUS IS ENTITLED TO TIERED ROYALTY PAYMENTS ON NET SALES OF ONPATTRO RANGING FROM 1.00% - 2.33% AFTER OFFSETS.ARBUTUS BIOPHARMA CORP - ROYALTY INTEREST HAS BEEN SOLD TO OMERS, EFFECTIVE AS OF JANUARY 1, 2019, FOR $20 MILLION.  Full Article

Arbutus Q1 Loss Per Share $0.47
Tuesday, 7 May 2019 

May 6 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALING $110.6 MILLION AS OF MARCH 31, 2019.BELIEVE CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO 2020.  Full Article

Arbutus Reports Q3 Loss Per Share $0.49
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.49.Q3 REVENUE $1.6 MILLION VERSUS $6.9 MILLION.Q3 REVENUE VIEW $211,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.  Full Article

Arbutus Appoints David Hastings As Chief Financial Officer
Friday, 8 Jun 2018 

June 7 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS STRENGTHENS MANAGEMENT TEAM WITH APPOINTMENT OF DAVID C. HASTINGS AS NEW CHIEF FINANCIAL OFFICER.ARBUTUS BIOPHARMA CORP - HASTINGS WILL ASSUME CFO ROLE FROM KOERT VANDENENDEN, ARBUTUS' INTERIM CHIEF FINANCIAL OFFICER..ARBUTUS BIOPHARMA CORP - APPOINTMENT OF DAVID HASTINGS AS CHIEF FINANCIAL OFFICER, EFFECTIVE JUNE 11.  Full Article

Arbutus Announces Corporate Update
Thursday, 15 Mar 2018 

March 14 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS.ARBUTUS BIOPHARMA CORP - ‍ARB-1467 PHASE II COMBINATION STUDY BEGINNING IN 1Q18​.ARBUTUS BIOPHARMA CORP - ‍INTERIM ON-TREATMENT RESULTS FROM ARB-1467 STUDY ARE EXPECTED IN SECOND HALF OF 2018, FOLLOWED BY FINAL RESULTS IN 2019 ​.ARBUTUS BIOPHARMA CORP - ‍AB-452 TO ENTER CLINICAL DEVELOPMENT​.  Full Article

Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology
Friday, 23 Feb 2018 

Feb 22 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY.ARBUTUS BIOPHARMA CORP - ‍SETTLEMENT TERMINATES ACUITAS' RIGHT TO USE OR SUBLICENSE OUR LNP TECHNOLOGY GOING FORWARD​.ARBUTUS BIOPHARMA - ‍SETTLEMENT STIPULATES THAT 4 NON-EXCLUSIVE VIRAL VACCINE SUBLICENSES PREVIOUSLY GRANTED TO MODERNA ARE ONLY SUBLICENSES TO SURVIVE​.ARBUTUS BIOPHARMA - LITIGATION INITIATED BY ACUITAS THERAPEUTICS ON OCT. 25, 2016 IN SUPREME COURT OF BRITISH COLUMBIA HAS BEEN SETTLED BEFORE TRIAL​.  Full Article

Arbutus Announces Departure Of CFO Bruce Cousins
Wednesday, 14 Feb 2018 

Feb 13 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO.BRUCE COUSINS, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, IS LEAVING CO BUT WILL REMAIN AVAILABLE ON A CONSULTING BASIS.‍KOERT VANDENENDEN, ARBUTUS' VICE PRESIDENT OF FINANCE, WILL SERVE AS INTERIM CHIEF FINANCIAL OFFICER​.‍COMPANY WILL PROMPTLY BEGIN A SEARCH FOR A PERMANENT CHIEF FINANCIAL OFFICER.​.  Full Article

Arbutus Consolidates HBV Business Around Warminster, PA Site
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA.ARBUTUS BIOPHARMA CORP - TO ACHIEVE ALIGNMENT, CO WILL REDUCE ITS GLOBAL WORKFORCE BY ABOUT 31 PERCENT AND PLANS TO CLOSE ITS BURNABY FACILITY.ARBUTUS BIOPHARMA CORP - WILL INCUR RESTRUCTURING COSTS RELATED TO WORKFORCE REDUCTION AND SITE CLOSURE OF ABOUT $5.0 MILLION.ARBUTUS BIOPHARMA CORP - ‍RESTRUCTURING COSTS WILL BE PRIMARILY PAID IN CASH IN Q2 OF 2018​.  Full Article

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​.  Full Article